Latest news with #privateplacement
Yahoo
9 hours ago
- Business
- Yahoo
BIOVAXYS ANNOUNCES AMENDED LIFE OFFERING
// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, June 20, 2025 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces that it has amended the terms of its brokered private placement LIFE financing (the "Offering") previously announced on May 30, 2025, and filed an amended offering document (the "Amended Offering Document"). The Amended Offering Document updates the exercise price of the common share purchase warrant that forms part of the units ("Units") being offered by the Company from a post-consolidation exercise price of $0.60 to a post-consolidation exercise price of $0.50. As previously announced, the Company intends to consolidate the common shares of the Company (the "Common Shares") on the basis of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the "Consolidation"), and complete a concurrent Offering consisting of a minimum of 5,714,285 Units at a post-Consolidation price of $0.35 per Unit for minimum gross proceeds of $2,000,000 and a maximum of 8,571,428 Units at a post-Consolidation price of $0.35 per Unit for maximum gross proceeds of up to $3,000,000. Each Unit will consist of one (1) post-Consolidation common share in the capital of the Company (each, a "Post-Consolidation Common Share") and one (1) Post-Consolidation Common Share purchase warrant (each, a "Post-Consolidation Warrant"). Each Post-Consolidation Warrant will entitle the holder thereof to purchase one Post-Consolidation Common Share at a post-Consolidation price of $0.50 for a period of 36 months from the closing date of the Offering. Closing of the Offering is anticipated to occur on or about June 30, 2025, or such other date as the Company may agree upon provided such date is on or before July 14, 2025. Closing of the Offering is subject to the satisfaction of certain conditions, including, but not limited to, acceptance by the CSE. The Company intends to use the net proceeds raised from the Offering for research and development, general corporate purposes and working capital. Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions ("NI 45-106"), the Units issuable under the Offering will be offered for sale to purchasers in all provinces and territories of Canada, except Quebec, pursuant to the listed issuer financing exemption ("LIFE") under Part 5A of NI 45-106. The securities to be issued pursuant to the sale of the Units under the Offering will not be subject to resale restrictions in accordance with applicable Canadian securities laws. There is an Amended Offering Document dated June 18, 2025, related to the Offering that can be accessed under the Company's profile at and on the Company's website at Prospective investors should read this offering document before making an investment decision. This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. About BioVaxys Technology Corp. BioVaxys Technology Corp. ( a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'neoantigen' tumor cell construct platform for refractive late-stage ovarian cancer. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the U.S. on the OTC Markets (OTCQB marketplace). For more information, visit and connect with us on X and LinkedIn. ON BEHALF OF THE BOARDSigned "James Passin" James Passin, Chief Executive OfficerPhone: +1 740 358 0555 Cautionary Statements on Forward Looking Information This news release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the future operating or financial performance of the Company, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, the proposed Consolidation, including the ratio thereof and timing thereof, and the Offering, including the size and use of proceeds, and the timing and ability of the Company to close the Offering, including obtaining approval of the Offering from the CSE. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by BioVaxys, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, the ability of the Company to complete the Consolidation and the Offering on the terms proposed or at all, and the ability to obtain necessary approvals, including the approval of the CSE. BioVaxys does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by applicable securities laws. The CSE has not reviewed, approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this news release. Logo: View original content: SOURCE BioVaxys Technology Corp. View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 hours ago
- Business
- Yahoo
Boron One Announces Closing of Financing
VICTORIA, BC / / June 19, 2025 / Boron One Holdings Inc. ("Boron One" or the "Company") [TSXV:BONE]") is pleased to announce that the Company has accepted subscriptions for 4,120,000 units at a price of $0.05 per unit, for gross proceeds of $206,000. Each unit is comprised of one common share and one common share purchase warrant, exercisable at $0.05 for one year, and $0.07 for 2 further years. The Common Shares and Warrants comprising the Units will be subject to a four-month and one day hold period in accordance with the policies of the TSX Venture Exchange and applicable securities legislation. The Company intends to use net proceeds of the Private Placement for working capital requirements. The Private Placement is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including approval from the TSX Venture Exchange. On behalf of the Board of Directors,Tim Daniels, President About Boron One Holdings Inc. Boron One Holdings Inc. is an international mineral exploration and development company with boron assets in Serbia. Headquartered in Victoria, B.C., Canada, Boron One's shares are traded on the TSX Venture Exchange under the symbol "BONE". For detailed information please see Boron One's website at or the Company's filed documents at For further information, please contact:Boron One Holdings Fallis, General ManagerPhone: 1-250- 384-1999 or 1-888-289-3746info@ Boron's Public Quotations:CanadaTSX Venture: BONEBerlin: EKVUS: SEC 12G3-2(B) #82-4432ERVFFOTCBB: ERVFF Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE: Boron One Holdings Inc. View the original press release on ACCESS Newswire
Yahoo
17 hours ago
- Business
- Yahoo
Volatus Aerospace Inc. Secures $3 Million in Financing from Existing Major Institutional Investor and Provides Corporate Update
/ NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TORONTO, June 19, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV: FLT) (OTCQX: TAKOF) (Frankfurt: ABB) ('Volatus' or the 'Company'), a leader in global aerial solutions, is pleased to announce the successful closing of a $3 million private placement (the 'Financing') from Investissement Québec. Pursuant to the Financing, the Company entered into an amended and restated secured convertible debenture (the 'Debenture') increasing the principal amount of Investissement Québec's original investment of $7.5 million, as announced in the Company's news release dated October 21, 2024, to an aggregate of $10.5 million. The Financing will allow Volatus to grow its operations and accelerate the development of its aerial solutions in key sectors ahead of the 2025 season, including oil and gas, energy utilities, public safety, and infrastructure. Volatus will also gain additional financial flexibility as it seeks to grow its services business globally. Global geopolitical turmoil has put a renewed focus on securing local assets, and Volatus' platforms and technology can play a key part of this strategy at scale and cost. 'We are honored to have additional support from Investissement Québec, which is a great vote of confidence as we continue to grow in our target markets', said Glen Lynch, CEO of Volatus. This Financing will enable the Company to achieve our near-term profitability goal and reinforce our base from which to go after global projects.' The Debenture, with a term of five years, will be senior secured and convertible at the holder's option into common voting shares of Volatus (the 'Common Shares') at a conversion price of $0.202 per Common Share (the 'Conversion Price'). The Debenture will bear interest at a rate of 12.5% per annum until its maturity date on October 21, 2029 (the 'Maturity Date'). The interest portion for the first three-year period will be initially non-cash interest, and capitalized semi-annually, and convertible, at the holder's option at the then market price of the Common Shares as permissible by securities regulations and the rules of the TSX Venture Exchange (the 'TSXV'), while the interest portion for the last two years will be payable, semi-annually, in cash until the Maturity Date, unless the Debenture is otherwise converted at the Conversion Price, at any time and at the holder's option before the Maturity Date. The Company intends to use the net proceeds from the Financing for financing inventory, capital expenditures, working capital and general corporate purposes. Certain existing aircraft related financing debt will remain secured in priority to the Debenture. Corporate Updates Volatus is also pleased to announce that, further to its press release dated May 22, 2025, the Company has completed its previously announced shares-for-debt transaction (the 'Shares-for-Debt Transaction') and issued a total of 3,720,000 units of the Company (the 'Settlement Units'), settling the principal and accrued and unpaid interest in the amount of $446,400.00 owing to holders of unsecured non-convertible debentures of the Company. Each Settlement Unit is comprised of one Common Share (a 'Settlement Share') and one common voting share purchase warrant of the Company (a 'Settlement Warrant'), with each Settlement Warrant exercisable to purchase one additional Common Share at an exercise price of $0.20 per Common Share for a period of 36 months from the date of issuance. The Debenture and Settlement Warrants will not be listed on a public stock exchange. The Financing and the Shares-for-Debt Transaction remain subject to the final approval of the TSXV. The Debenture, the Common Shares issuable upon conversion of the Debenture and the securities issuable in connection with the Shares-for-Debt Transaction are subject to a statutory hold period of four months plus a day from the date of issuance of the Debenture and Settlement Units, as applicable, in accordance with applicable securities legislation and policies of the TSXV. Additionally, the Settlement Shares and the Common Shares issuable upon the conversion of the Debenture or the exercise of the Settlement Warrants will not be listed on a U.S. public stock exchange and have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration. Additionally, in support of its commitment to aligning employee incentives with long-term shareholder value, the Company has issued a total of 2,900,000 restricted share units ('RSUs') to employees under its approved equity incentive plan. CEO Glen Lynch has voluntarily chosen to forgo participation in this RSU grant, allowing the benefits to extend across the organization. He continues to demonstrate his confidence in the Company's long-term success as a significant equity holder. About Volatus Aerospace: Volatus Aerospace is a leader in innovative global aerial solutions for intelligence and cargo. With a strong foundation of over 100 years of combined institutional knowledge in aviation, Volatus provides comprehensive solutions using both piloted and remotely piloted aircraft systems. We serve industries such as oil and gas, utilities, healthcare, and public safety. Our mission is to enhance operational efficiency, safety, and sustainability through cutting-edge, real-world solutions. Forward-Looking Information This news release contains statements that constitute 'forward-looking information' and 'forward-looking statements' within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs, and current expectations of the Company with respect to future business activities and operating performance. Often, but not always, forward-looking information and forward-looking statements can be identified by the use of words such as 'plans', 'expects', 'is expected', 'budget', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates', or 'believes' or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results 'may', 'could', 'would', 'might' or 'will' (or other variations of the foregoing) be taken, occur, be achieved, or come to pass. Forward-looking information includes information about the Financing, the Debenture and the Shares-for-Debt Transaction, including information regarding the use of proceeds of the Financing and TSXV final approval of the Financing and the Shares-for-Debt Transaction. Forward-looking information is based on currently available competitive, financial, and economic data and operating plans, strategies, or beliefs of management as of the date of this news release, but involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors may be based on information currently available to the Company, including information obtained from third-party industry analysts and other third-party sources, and are based on management's current expectations or beliefs. Any and all forward-looking information contained in this news release is expressly qualified by this cautionary statement. Investors are cautioned that forward-looking information is not based on historical facts but instead reflects expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Forward-looking information and forward-looking statements reflect the Company's current beliefs and is based on information currently available to it and on assumptions it believes to be not unreasonable in light of all of the circumstances. In some instances, material factors or assumptions are discussed in this news release in connection with statements containing forward-looking information. Such material factors and assumptions include, but are not limited to TSXV final approval of the Financing and the Shares-for-Debt Transaction and including, but not limited to, those factors set forth in the Company's annual and quarterly management's discussion and analysis filed on Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. The forward-looking information contained herein is made as of the date of this news release and, other than as required by law, the Company disclaims any obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release. Contact Information:Abhinav Singhvi, CFO +1-833-865-2887Sign in to access your portfolio
Yahoo
a day ago
- Business
- Yahoo
Ísfélag hf. participation in financing of Austur Holding AS in connection with Kaldvik AS share capital increase
Ísfélag hf. (the 'Company'), which holds a 29.3% stake in Austur Holding AS ('Austur'), hereby announces its participation in the financing of Austur in relation to Austur's subscription in a share capital increase of Kaldvik AS, following the approval of an extraordinary general meeting of Kaldvik AS on 19 June 2025. Kaldvik AS, listed on Nasdaq First North Growth Market and Euronext Growth in Oslo, announced on 5 June 2025 the results of a private placement of 38,011,500 new shares for a total subscription amount of NOK 532 million, equivalent to approximately EUR 46.2 million. Austur was allocated 27,045,027 shares, representing approximately 71.2% of the total allocation, for a total subscription amount of NOK 378.6 million, or approximately EUR 33 million. The allocation of new shares was i.a. subject to approval by the extraordinary general meeting of Kaldvik AS. Furthermore, following the private placement, the purchase by Austur of an additional 860,000 shares in Kaldvik AS was announced on 10 June 2025. Following shareholder approval of the share capital increase in Kaldvik AS on 19 June 2025, Austur is obliged to settle its allocated portion of the new shares pursuant to the private placement. In accordance with a financing agreement between Austur and its shareholders, Ísfélag will provide financing in connection with the aforementioned transactions in the amount of NOK 341 million (approximately EUR 29.7 million), comprising an equity contribution and in the form of convertible shareholder loans. Following these transactions Austur shareholding in Kaldvik AS will be a 57.35% but was previously 54,06%. The investment forms part of the Company's strategy to diversify its revenue streams and to support the continued development of Kaldvik in to access your portfolio
Globe and Mail
a day ago
- Business
- Globe and Mail
HPQ Announces Closing of Non-Broker Private Placement
MONTREAL, June 19, 2025 (GLOBE NEWSWIRE) -- HPQ Silicon Inc. ('HPQ' or the 'Company') (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08), a technology company driving innovation in advanced materials and critical process development, is pleased to announce it has closed yesterday a Non-Brokered Private placement financing first announced on May 29, 2025 for 3,158,000 units at a price of $0.18 per unit for a gross proceed of $568,440. Each Unit is comprised of one (1) common share and one (1) common share purchase warrant of the Company. Each Warrant will entitle the holder thereof to purchase one common share of the capital stock of the Company at an exercise price of $ 0.25 for a period of 48 months from the date of closing of the placement. Each share issued pursuant to the placement will have a mandatory four (4) month and one (1) day holding period from the date of closing of the placement. 'Closing this financing in less-than-ideal market further demonstrates the strong interest in HPQ's value proposition,' said Bernard Tourillon, President and CEO of HPQ Silicon Inc. 'Through modest in size, this financing provides HPQ with a solid foundation to capitalize on the larger opportunities we are actively pursuing.' Mr. Bernard Tourillon, Chairman, President, CEO and Director of HPQ, directly or via entities under his controls, subscribed for 1,112,000 units in the placement. Following the completion of the private placement, Mr. Tourillon will beneficially own or exercise control or direction over, directly or indirectly, 21,052,041 shares, representing 4.97 per cent of the issued and outstanding Common Shares of the Company. Mrs. Noëlle Drapeau, HPQ Corporate Secretary and a Director, personally and though its company 6710018 Canada Inc., subscribed for 150,000 units in the placement. Following the completion of the private placement, Mrs. Drapeau will beneficially own or exercise control or direction over, directly or indirectly, 1,201,500 shares, representing 0.28 per cent of the issued and outstanding common shares of the company. The participation of Mr. Tourillon and Mrs. Drapeau in the private placement constitutes a related party transaction within the meaning of Multilateral Instrument 61-101 -- Protection of Minority Security Holders in Special Transactions, and TSX Venture Exchange Policy 5.9 -- Protection of Minority Security Holders in Special Transactions. In connection with this related party transaction, the company is relying on the formal valuation and minority shareholder approval exemptions of subsections 5.5(a) and 5.7(1)(a) of MI 61-101, respectively, as the fair market value of the portion of the private placement subscribed by Mr. Tourillon and Mrs. Drapeau does not exceed 25 per cent of the company's market capitalization. The Board of directors of the Company has approved the Private Placement, including the participation of Mr. Tourillon and Mrs. Drapeau therein. In connection with the placement, Stephen Avenues Securities Inc. of Toronto, Ontario, received a cash commission equal to $ 10,260 and the Company issued to them 57,000 broker warrants, and Research Capital of Toronto, Ontario received a cash commission equal to $ 1,512 and the Company issued to them 8,400 broker warrants. Each Broker Warrant will entitle the Broker to acquire one common share of the company at a price of $0.25 per share for a period of 48 months following the Closing Date and is subject to the mandatory four (4) month and one (1) day holding period from the date of closing of the placement as the warrants of the placement. SHARES FOR DEBT SETTLEMENT HPQ has completed the debt settlement announced on June 12 th, 2025, by issuing 565,000 units at a price of $0.18 per unit thereby settling the outstanding invoices totaling the amount of $101,700. Each Unit is comprised of one (1) common share and one (1) common share purchase warrant of the Company. Each Warrant will entitle the holder thereof to purchase one common share of the capital stock of the Company at an exercise price of $ 0.25 for a period of 48 months from the date of closing of the transaction. Each share issued pursuant to the debt settlement will have a mandatory four (4) month and one (1) day holding period from the date of closing of the transaction. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the ' U.S. Securities Act ') or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. About HPQ Silicon HPQ Silicon Inc. (TSX-V: HPQ) is a Quebec-based TSX Venture Exchange Industrial Issuer. HPQ is a technology company focused on innovation in advanced materials and critical process development. In partnership with world-class technology leaders PyroGenesis Inc. and NOVACIUM SAS —of which HPQ is a shareholder—the company is developing the materials and process technologies essential to achieving net-zero goals. HPQ activities are centred around the following pillars: Becoming a green, low-cost (Capex and Opex) manufacturer of Fumed Silica using the FUMED SILICA REACTOR, a proprietary technology owned by HPQ Silica Polvere Inc., being developed for HSPI by PyroGenesis. Working with R&D partner NOVACIUM SAS, to become a producer of silicon-based anode materials for battery applications. Developing Innovative processes to generate and use Hydrogen: METAGENE™, a low-carbon, chemical-based, on-demand, high-pressure autonomous hydrogen production system, is being developed by NOVACIUM SAS of which HPQ holds the exclusive North American (Canada, USA, and Mexico) license. WASTE TO ENERGY (W2E), a new process to transform black aluminum dross into a valuable resource, is being developed by NOVACIUM SAS, of which HPQ holds the exclusive North American (Canada, USA, and Mexico) license. HPQ is also a shareholder in NOVACIUM SAS. Becoming a zero-CO 2 low-cost (Capex and Opex) producer of High Purity Silicon (2N+ to 4N) using our PUREVAP™ 'Quartz Reduction Reactors' (QRR), a proprietary technology owned by HPQ being developed for HPQ by PyroGenesis. For more information, please visit HPQ Silicon web site. Disclaimers: This press release contains certain forward-looking statements, including, without limitation, statements containing the words "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", "in the process" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company's ongoing filings with the security's regulatory authorities, which filings can be found at Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This News Release is available on the company's CEO Verified Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.
